Targeting gangliosides to treat Alzheimer’s and Parkinson’s diseases: A disruptive approach with the first-in-class peptide AmyP53 Neural Regeneration Research . 2026, (6): 2419 -2420 .  DOI: 10.4103/NRR.NRR-D-25-00076